Neumora Therapeutics, Inc. (NMRA)

Neumora Therapeutics' stock has been significantly impacted by clinical trial results. In January 2025, the stock price plummeted after disappointing results from the KOSTAL-1 trial. BofA Securities reduced its price target for NMRA shares, but maintained a Buy rating. The stock's 52-week range has been between $0.61 and $3.65, with a 199.21% change over the past year. As of early April 2026, the share price was around $2.00, representing a 165.53% increase over the period from April 7, 2025. The company reported its fourth-quarter and full-year 2025 financial results on March 30, 2026.

As a clinical-stage biopharmaceutical company, Neumora Therapeutics, Inc. is primarily focused on the research, development, and clinical trials of its product candidates. Its products are not yet commercially available on the market, therefore, there is no discernible demand seasonality for its products or services at this stage. Demand will be driven by clinical trial outcomes and eventual market approval and adoption.

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision medicine for brain diseases, operating within the Health Technology sector and Biotechnology industry. The company aims to address the global brain disease crisis by developing targeted medicines using data science and neuroscience. Its pipeline includes Navacaprant (NMRA-140) for major depressive disorder, NMRA-511 for agitation associated with dementia due to Alzheimer's disease, NMRA-898 for schizophrenia, and NMRA-215 for obesity.

Neumora Therapeutics, Inc. is headquartered in Watertown, Massachusetts, USA, with additional locations in the Greater Boston area and South San Francisco.

Neumora Therapeutics' brand reputation is built on its mission to redefine neuroscience drug development and bring forward novel therapies for brain diseases using a precision medicine approach. The company emphasizes its commitment to improving the lives of patients with brain diseases by targeting novel mechanisms of action. However, the company's reputation was likely impacted by the disappointing results of the KOSTAL-1 trial for navacaprant in January 2025, which led to a significant drop in stock price and market skepticism. Additionally, an opportunity for investors to join a fraud investigation with the Schall Law Firm was announced in April 2026, which could also affect public perception. Despite these setbacks, some analysts remain optimistic about the company's prospects, citing the potential of its other pipeline candidates.

Neumora Therapeutics, Inc. has a diverse ownership structure, including institutional, insider, and retail investors. As of April 2026, the company has 109 institutional owners and shareholders holding a total of 63,088,441 shares. Major institutional owners include Softbank Group Corp, Vanguard Group Inc, MIC Capital Management UK LLP, Point72 Asset Management, L.P., Millennium Management Llc, Fmr Llc, WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST, ICONIQ Capital, LLC, Lunate Capital Ltd, Amgen Inc., and Arch Venture Partners, L.P. Approximately 47.65% of the stock is held by institutions, while insiders hold 26.80%.